Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.
OBJECTIVE
A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update.


METHODS
New data were presented, discussed and debated in an expert pre-meeting to draft a revision. The revised contents were finalized after discussion in a general meeting of APASL.


RESULTS
Conceptual background, including the efficacy and safety profile of currently available and emerging drugs, was reviewed. Nineteen recommendations were formed and unresolved issues and areas for further study were suggested.


CONCLUSIONS
The current therapy of chronic hepatitis B is modestly effective but not satisfactory. The development of new drugs and new strategies is required to further improve the outcomes of treatment.
Liaw
Yun-Fan
YF
Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan. liveryfl@so-net.net.tw
Leung
Nancy
N
Guan
Richard
R
Lau
George K K
GK
Merican
Ismail
I
McCaughan
Geoff
G
Gane
Edward
E
Kao
Jia-Horng
JH
Omata
Masao
M
D000998:Antiviral Agents / Q000627:therapeutic use*; D001208:Asia; D001315:Australia; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D009520:New Zealand; D010139:Pacific Islands; D017410:Practice Guidelines as Topic
D000998:Antiviral Agents